In a world where we can summon cabs with a tap, binge entire seasons with a voice command, and chat with AI as if it were a friend—drug discovery still moves like it’s trapped in the dial-up era. Billions are being poured into pharmaceutical R&D, and mind-blowing advances in AI predict targets we never thought possible. Yet, there’s a disconnect: the path from breakthrough idea to validation in the lab remains painfully slow and cumbersome. For us, this disconnect was more than a mere annoyance—it was a catalyst for change, a moment that lit the fuse on our mission to transform an entire industry. That spark became Bynd—and this is its origin story.
Act I: A Crumbling Status Quo
Our journey began with a simple, nagging observation: although labs worldwide had the capacity to take on new projects and validate novel drug targets, biotechs struggled to tap into that capacity effectively. At the same time, a surge in lab automation offered promising solutions—yet often failed to address fundamental barriers in real-world collaboration. As we talked to teams doing life-changing research, we kept hearing the same refrain from those working with CROs:
• Contracts often took weeks just to produce an initial draft—long before actual negotiations could even begin.
• Quotes were either incomplete or buried under red tape.
• Timelines slipped because data was siloed in email attachments or proprietary tools.
• Scientists struggled to justify the cost of working with CROs, unable to grasp the tangible value behind a tangle of processes.
It was like seeing a sleek, cutting-edge vehicle stuck in first gear: powerful technology overshadowed by outdated workflows. We knew there had to be a better way.
Act II: The AI Explosion and the Missing Bridge
Then came the AI wave. We took a deep interest in protein language models and their uncanny ability to generate entirely new, testable sequences—sometimes from the comfort of a computational biologist’s armchair. It was staggering, exhilarating, and completely impractical to validate everything in-house. Think of a visionary engineer designing thousands of prototypes but lacking the production capacity to manufacture them all.
The answer? Outsource. But forming those partnerships introduced a whole new layer of friction—painstaking phone calls, ambiguous proposals, mismatched expectations, and no straightforward “developer toolkit” or REST API to automate the process. A few forward-thinking organizations had built custom pipelines for ordering lab work at the click of a button, but the vast majority were left navigating bureaucratic mazes just to get a single study started.
The result? A state-of-the-art AI engine with no efficient pipeline to turn insights into actionable data. The potential for groundbreaking new therapies was out there, waiting to be realized—but the system’s complexity was holding everyone back.
Act III: A Shaken, Fragmented Industry
As if AI-driven discovery weren’t complex enough, we saw two extremes of biotech strategy:
1. Virtual Biotechs: Operating with no physical labs—nimble, AI-led, and completely reliant on contract research organizations (CROs) to execute.
2. In-House Giants: Investing millions in massive lab automation systems, only to mothball them when pivoting to new therapeutic areas. Automation wasn’t the magic switch they hoped it would be; if the technology couldn’t be retooled quickly, the investment was left gathering dust.
Meanwhile, CROs themselves battled outdated quoting processes and labyrinthine communication pipelines. Many were outstanding at the science but undercut by clunky commercial systems. Others struggled to juggle an avalanche of calls, emails, and vaguely defined projects.
It was a sprawling cinematic universe with no central hub—no single point of contact, no seamless pipeline, no spark to unite these disparate teams and technologies. Fragmentation was the norm, and each faction was left struggling on its own.
(to be continued…)
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.